# data[].attributes.body
I think this can be an excellent adjunctive therapy. In today's technologically driven world, everyone has a cell phone but not everyone with mental illness is wiling to seek therapy. I feel this could make a person feel less stigmatized and more comfortable in the comforts of wherever they choose instead of a clinical setting. I also feel that people may be more willing to be truthful to an app rather than a person face to face.

# data[].attributes.body
Daisy-Developer: I chose Daisy because this is a brand-new undiscovered territory. I feel she would be innovative in developing a plan to launch this tool.

Cindy-Connectedness: I chose Cindy because she will be able to bridge the gap associated with the stigma attached to mental health care and treatment.

Faith-Futuristic: I chose Faith because technology is our future. I feel that she will be able to maximize the explanations of the benefits of a therapeutic smart phone app.

Amelia-Adaptability: I chose Amelia because she will be very beneficial in helping our providers adapt from traditional treatment options to more technologically advanced treatments.

Mathew-Maximizer: I chose Mathew because he will be able to maximize the app’s potential for effective provider and patient education.

# data[].attributes.body
Input: You are inquisitive. You collect things. You might collect information—words, facts, books, and quotations—or you might collect tangible objects such as butterflies, baseball cards, porcelain dolls, or sepia photographs. Whatever you collect, you collect it because it interests you. This will help my team find new avenues to help educate patients on a new style of therapy.

Belief: If you possess a strong Belief theme, you have certain core values that are enduring. These values vary from one person to another, but ordinarily your Belief theme causes you to be family-oriented, altruistic, even spiritual, and to value responsibility and high ethics—both in yourself and others. I will stand behind my team and encourage with my strong belief in decreasing the stigma of mental health care.

Achiever: Your Achiever theme helps explain your drive. Achiever describes a constant need for achievement. You feel as if every day starts at zero. By the end of the day you must achieve something tangible in order to feel good about yourself. And by “every day” you mean every single day. I will be driven from day one to see this plan into fruition.

Intellection: You like to think. You like mental activity. You like exercising the “muscles” of your brain, stretching them in multiple directions. This need for mental activity may be focused; for example, you may be trying to solve a problem or develop an idea or understand another person’s feelings. I will find new ways to incorporate new technology into traditional care.

Learner: You love to learn. The subject matter that interests you most will be determined by your other themes and experiences, but whatever the subject, you will always be drawn to the process of learning. The process, more than the content or the result, is especially exciting for you. I will help my team by being diligent in research and learning new ways to evolve excellent patient care.

# data[].attributes.body
April 01, 2024

# data[].attributes.body
Otsuka Pharmaceutical and Click Therapeutics have announced that the FDA has cleared Rejoyn, a prescription digital therapeutic smart phone app aimed at treating major depressive disorder symptoms as an aide to standard outpatient care for adults aged 22 and older who are on antidepressants. Rejoyn is a six-week program designed to enhance cognitive control over emotions through validated training exercises and therapeutic lessons.

Rejoyn targets the neural networks affected by depression and utilizes brain-training exercises to improve emotional processing and regulation. It aims to provide a new option for patients who may not fully respond to traditional treatments. The app will require a prescription and is expected to be available for download in late 2024.

# data[].attributes.attachment_link.title
Rejoyn Becomes First Prescription Digital Therapeutic Authorized for Treatment of MDD

# data[].attributes.attachment_link.description
The FDA has cleared the first prescription digital therapeutic for major depressive disorder, Rejoyn.

# data[].attributes.attachment_link.title
Psychologist explains new digital depression treatment, Rejoyn

# data[].attributes.body
Kuntz, L. (2024). Rejoyn becomes first prescription digital therapeutic authorized for treatment of MDD. Psychiatric Times.

https://www.psychiatrictimes.com/view/rejoyn-becomes-first-prescription-digital-therapeutic-authorized-for-treatment-of-mdd

Roman, J. (2024). Otsuka and click therapeutics announce the U.S. food and drug administration clearance of rejoyn, the first prescription digital therapeutic authorized for the adjunctive treatment of major depressive disorder symptoms.

https://www.otsuka-us.com/news/rejoyn-fda-authorized

# data[].attributes.body
Otsuka Pharmaceuticals, Ltd

Tarek Rabah, B.S., B.A.

President and CEO.

" We truly work to change likes at Otsuka- I am continuously inspired by Otsuka-people to uncover new ways to advance innovative health solutions, and for the opportunity to make an impact in the lives of those we serve."

Click Therapeutics, Inc.

David B. Klein, B.A.

CEO

"It is our core belief that high quality digital therapies can offer safe and effective treatments, and will become a routine part of standard of care clinical practice"

# data[].attributes.attachment_link.title
Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn™, the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms | Otsuka US

# data[].attributes.attachment_link.description
Otsuka Pharmaceutical, Co. Ltd. and Click Therapeutics, Inc., announce that the U.S. Food and Drug Administration has cleared Rejoyn™ (developed as CT-152), the first prescription digital therapeutic authorized for the treatment of major depressive disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. Rejoyn is intended to reduce MDD symptoms.